Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Healthy Extracts Inc. (HYEX)
USD1.56
-0.19 (-10.86%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
1 Silvermound 80127
Littleton, CO, US
Littleton, CO, US
CEO
J. Scott Landers
Website
healthyextractsinc.com
IPO
2015-11-11
CIK 1630176 ISIN US42227D2099
Description
Healthy Extracts Inc., through its various divisions, specializes in the global and domestic research, development, and sale of natural botanical products. Its portfolio encompasses dietary supplements crafted for cardiovascular wellness, alongside KETONOMICS-branded neuro-enhancers aimed at boosting cognitive functions like memory, mental acuity, concentration, and neural energy. The company further supplies encapsulated bergamot products, available under distinct labels such as BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, and BergaMet SPORTSHEART. These bergamot offerings are distributed via its online platform and various other channels. Established in 2014 and based in Littleton, Colorado, the company was previously known as Grey Cloak Tech Inc. until its name change in October 2020.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.56
-0.19 (-10.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
430
Beta
-0.79
Float Shares
826.2K
Free Float %
27.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +16.34% | +99.12% | +100.89% | -4.26% | +13.07% | +48.03% | +12.50% | -66.06% | -72.83% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.56
Ratings Trend (MoM)
| Rating | 2026-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.08
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+44.9% ★ Q1'26: +73.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+66.2% ★ Q1'26: +90.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-13.0% Q1'26: +6.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-20.9% Q1'26: -20.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-3.6% Q1'26: -5.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+212.4% Q1'26: +464.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-3.33× Q1'26: -1.95× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|
| Revenue |
4.51M
est: 5.09M (-11.3%)
|
14.12M
14.12M – 14.12M
+177.6% YoY
|
| EBITDA |
-791.7K
est: -2.58M (+69.4%)
|
-7.17M
-7.17M – -7.17M
-177.6% YoY
|
| EBIT |
-943.9K
est: -2.62M (+64.0%)
|
-7.27M
-7.27M – -7.27M
-177.6% YoY
|
| Net Income |
-881.1K
est: -279.2K (-215.6%)
|
1.21M
1.21M – 1.21M
+533.3% YoY
|
| SGA |
3.37M
est: 5.85M (-42.4%)
|
16.24M
16.24M – 16.24M
+177.6% YoY
|
| EPS |
-0.09
est: -0.03 (-215.7%)
|
0.13
0.13 – 0.13
+533.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
745.8K
OE per share TTM
0.02
Owner's Yield
1.96%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
30.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PERSONS ( | 43.65M | 40.17% | 43.65M | — | 43.65M | — | IN | United States | 2017-05-01 | ↗ |
| 2 | 47-3168266 | 4.66M | 9.99% | 4.66M | 4.66M | 4.66M | 4.66M | PN | Delaware | 2017-09-29 | ↗ |
| 3 | (45-5405850) | 1.50M | 9.80% | 1.50M | 1.50M | 1.50M | 1.50M | PN | FLORIDA | 2016-08-19 | ↗ |
| 4 | 82-1042853 | 222.2K | 8.99% | 222.2K | — | 222.2K | — | OO | New York | 2018-09-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-19 | Swanson Donald William | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 13,075,920 | 23,536,656.00 | 307.76T | 13,075,920 | D | ↗ |
| 2023-06-30 | Croyle William Russell Jr | Director | A-Award | A | Common Stock | 500,000 | 5.00 | 2.50M | 500,000 | — | ↗ |
| 2022-05-31 | Madden Robert Michael | Officer | — | D | Common Stock Options | 0 | 0.05 | — | 0 | — | ↗ |
| 2021-12-31 | Croyle William Russell Jr | Director | A-Award | A | Common Stock Options | 200,000 | 0.05 | 10.0K | 500,000 | — | ↗ |
| 2020-04-13 | Pitts Kevin | Officer / 10% Owner | A-Award | A | Common Stock | 610,112 | 0.00 | — | 2,230,112 | — | ↗ |
| 2019-12-20 | Pitts Kevin | Officer / 10% Owner | P-Purchase | A | Common Stock Options | 200,000 | 0.05 | 10.0K | 2,200,000 | — | ↗ |
| 2019-09-24 | Croyle William Russell Jr | Director | — | D | Common Stock | 0 | 0.00 | — | 663,670 | — | ↗ |
| 2019-02-13 | Pitts Kevin | Officer / 10% Owner | A-Award | A | Common Stock | 1,620,000 | 0.00 | — | 1,620,000 | — | ↗ |
| 2019-02-04 | Javia Sanjeevkumar Ratanshi | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-11-20 | Pitts Kevin | Director / Officer / 10% Owner | P-Purchase | A | Series A Convertible Preferred Stock | 250,000 | 0.00 | — | 598,601 | — | ↗ |
| 2018-09-28 | Pitts Kevin | Director / Officer / 10% Owner | P-Purchase | A | Series A Convertible Preferred Stock | 348,601 | 0.00 | — | 576,435 | — | ↗ |
| 2017-10-17 | Stiles Patrick | Director / Officer / 10% Owner | — | D | Series A Convertible Preferred Stock | 51,457,126 | 0.00 | — | 0 | — | ↗ |
| 2017-10-17 | Pitts Kevin | Director / Officer / 10% Owner | — | I | Series A Convertible Preferred Stock | 20,402 | 0.00 | — | 0 | — | ↗ |
| 2017-10-17 | COVELY FRED | Director / Officer / 10% Owner | A-Award | A | Series A Covertible Preferred Stock | 41,403 | 0.00 | — | 41,403 | — | ↗ |
| 2017-10-17 | BOSSUNG WILLIAM C | Director / Officer / 10% Owner | A-Award | A | Series A Convertible Preferred Stock | 146,330 | 0.00 | — | 146,330 | — | ↗ |
| 2017-05-19 | Nejman Joseph | Director / Officer / 10% Owner | J-Other | D | Series A Convertible Preferred Stock | 6,024,536 | 0.00 | — | 0 | — | ↗ |
| 2017-03-31 | Nejman Joseph | Director / Officer / 10% Owner | D-Return | D | Common Stock | 19,001,105 | 0.00 | — | 7,500,000 | — | ↗ |
| 2016-05-11 | BOSSUNG WILLIAM C | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 400,000 | 0.13 | 50.0K | 3,600,000 | — | ↗ |
| 2016-01-19 | DUNN BRIAN J | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2016-01-19 | COVELY FRED | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2016-01-19 | BOSSUNG WILLIAM C | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-471.9K
Shares Outstanding
3.02M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donald Swanson | Chief Executive Officer & Chairman | 192.0K | male |
| Kevin Pitts | President, Chief Operating Officer, Treasurer & Director | 125.0K | male |
| Robert Madden | Chief Financial Officer & Secretary | 114.0K | male |
| J. Scott Landers | Executive Vice President of Sales & Marketing | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HYEX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
